Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?
- Written by: Steve Macfarlane, Head of Clinical Services, Dementia Support Australia, & Associate Professor of Psychiatry, Monash University
ShutterstockTrial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.
But as usual, there’s more to the story. The study only included people with early or mild disease, not more advanced...
